Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lysine acetylsalicylate + glycine is a pharmaceutical combination consisting of the lysine salt of aspirin (acetylsalicylic acid) and the amino acid glycine. Lysine acetylsalicylate is a highly water-soluble prodrug of aspirin, which allows for rapid systemic absorption and the potential for parenteral or inhaled administration. Aspirin acts as an irreversible inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), thereby blocking the synthesis of prostaglandins and thromboxanes, which are key mediators of pain, inflammation, and platelet aggregation. Glycine is included in the formulation primarily as a buffering agent to improve gastric tolerance and reduce mucosal irritation. This combination is widely used for the acute treatment of migraine attacks, moderate-to-severe pain, and fever. Aspiair GmbH has specifically developed an inhaled dry-powder formulation (AS-001) of lysine acetylsalicylate to provide rapid relief for migraine patients, bypassing the gastrointestinal tract and avoiding the delays in absorption often caused by migraine-associated gastric stasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lysine acetylsalicylate + glycine.